Semaglutides
Culture

FDA calls Novo Nordisk's Wegovy pill TV ad false or misleading

The FDA says a TV commercial for the oral Wegovy pill claimed more than the evidence shows, a reminder that ad claims for GLP-1 medicines are not the same as proven head-to-head results.

By the Semaglutides news desk··Wegovy

The FDA's Office of Prescription Drug Promotion has determined that a television commercial for the Wegovy pill is false or misleading, according to an untitled letter sent to Novo Nordisk and dated Feb. 5, 2026 [1]. The agency said the ad misbrands Wegovy, the oral semaglutide product, and that distributing the drug while such promotion continues violates the Federal Food, Drug, and Cosmetic Act [1].

The commercial, logged as "January 2026 Pill Spot" (US25SEMO01839), was filed with the FDA on Form 2253 [1]. It introduces "Wegovy pill," calls it "the first and only FDA approved GLP-1 weight loss pill," and closes on taglines built around "Live lighter," including "Now you can live lighter by losing weight" [1]. The BMJ reported that the spot was part of Novo's "Live lighter" campaign and debuted Jan. 11, 2026, during the Golden Globes broadcast [3].

Taken together, the letter says, those lines imply that the pill form gives Wegovy an edge over other GLP-1 weight-loss medicines — better efficacy, better safety, or both — and that patients can now reach results earlier GLP-1s could not deliver [1]. The FDA singled out "live lighter" and "a way forward," writing that they suggest extra weight loss relative to other approved GLP-1 treatments "when this has not been demonstrated" [1]. The agency said the same phrases point to non-physical payoffs, listing "emotional relief, reduced psychological burden, hope, or direction for patients' lives," and that this frames the drug as "a solution to broader life challenges rather than a treatment for a specific condition" [1][2].

Wegovy's prescribing information describes the oral 25 mg once-daily tablet as tested in a placebo-controlled trial [1]. The FDA said it is not aware of data showing the oral product is superior to other approved GLP-1 weight-loss drugs on efficacy or safety, and it asked Novo to submit any supporting data if the company has it [1].

Risk disclosure was a second problem. According to the letter, the commercial's major statement included on-screen text that did not match the corresponding audio, so the risks were not delivered in audio and text at the same time — a dual-modality requirement for TV drug ads [1].

Novo confirmed it received the letter. Liz Skrbkova, the company's head of U.S. media and stakeholder relations, said the ad has run since the pill's launch but is not Novo's Super Bowl spot, and that the company is responding to the FDA [2]. "We take all regulatory feedback seriously and are in the process of responding to the FDA to address their concerns regarding the advertisement's presentation," she said [2].

Oral Wegovy entered the U.S. market in January 2026 as the first GLP-1 pill approved for obesity, and Novo has said more than 170,000 Americans were already taking it [2]. Bloomberg first reported on the FDA letter [2]. On the same day the news broke, Novo sued the telehealth company Hims & Hers over compounded versions of Wegovy [2].

Why it matters for patients

An untitled letter is a finding about advertising, not a safety finding, and it does not question whether oral Wegovy works [1]. The objection is to how the commercial described the drug [1]. A practical consequence is that ads patients see for GLP-1 medicines can be rewritten or taken off the air [1].

The letter also separates a new dosage form from better outcomes. The oral tablet was compared with placebo in its trial, not with another GLP-1, and the FDA said it has seen no data showing the pill beats those medicines [1]. That gap between how a medicine is advertised and what its trials measured is the reason the agency acted [1][2].

What happens next

Novo's written response is due within 15 working days of receiving the letter. The FDA asked the company to list every promotional communication containing similar claims, along with its 2253 submission dates, and to explain how it will discontinue those communications or stop distributing Wegovy [1]. The agency noted that its list of concerns may not be complete [1]. Whether the commercial is still airing, and how the FDA will respond to Novo's answer, has not been reported [1][2].

Sources

  1. https://www.fda.gov/media/191020/download
  2. https://www.cnbc.com/2026/02/09/fda-novo-nordisk-wegovy-tv-ad.html
  3. https://www.bmj.com/content/392/bmj.s304
  4. https://www.cnbc.com/2026/08/05/novo-nordisk-stock-guidance-earnings-wegovy-ozempic-eli-lilly.html
  5. https://www.drugdiscoverytrends.com/novo-slashes-us-glp-1-prices-by-up-to-70-but-2026-semaglutide-revenue-could-hold-steady-or-even-grow

Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.